Anavex Life Sciences Corp.
AVXL · NASDAQ
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Market Cap | $759 | $474 | $523 | $794 |
| - Cash | $103 | $132 | $151 | $149 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $656 | $342 | $372 | $645 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | $0 | $5 | -$56 | -$51 |
| % Margin | – | – | – | – |
| Net Income | $0 | -$43 | -$48 | -$48 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.54 | -0.52 | -0.6 | -0.62 |
| % Growth | -3.8% | 13.3% | 3.2% | – |
| Operating Cash Flow | -$39 | -$31 | -$28 | -$24 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$39 | -$31 | -$28 | -$24 |